Session 4: Late Breaking Clinical Data for Prostate Cancer Patients
8:05 AM – 9:20 AM
Moderators:
Howard Soule, PhD
Prostate Cancer Foundation
Introduction
Howard Soule, PhD
Prostate Cancer Foundation
Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipatential150 Phase 3 Trial
Johann de Bono, MD, PhD
The Institute of Cancer Research; Royal Marsden Hospital, London, UK
Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System
Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell–Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Wm. Kevin Kelly, DO
Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center
Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer
Dimitris Skokos, PhD
Regeneron Pharmaceuticals
Elizabeth Miller, MD
Regeneron Pharmaceuticals
Live Session Discussion
9:20 AM – 9:25 AM Please Return to the Virtual Lobby to Join the Next Session